Resolution Therapeutics

Resolution is a clinical stage company developing macrophage cell therapies to repair inflammatory organ damage.

Syncona co-founded Resolution following a two year collaboration with researchers at the University of Edinburgh and the Scottish National Blood Transfusion Service.

Resolution is developing macrophage cell therapies to repair inflammatory organ damage, including treatment of end-stage chronic liver disease. Macrophages are cells of the innate immune system which orchestrate the body’s defence against infection and injury; the company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings.

Resolution's lead programme, RTX001, is in a Phase I/II trial in end-stage liver disease, with an interim data readout expected in H2 CY2026. Positive four-year follow-up data from the University of Edinburgh's MATCH trial of regenerative macrophage therapy in patients with liver cirrhosis further validates the approach.